Jump to content
Medicinal Wolverine
Medicinal Wolverine

The studies you can check for yourself

BPC-157 TB-500 references identify the tests behind the claims

When your pain hangs on, a confident claim may deserve a closer look. These links lead to the research and FDA pages. The numbers connect each claim with its supporting source.

Read the findings in plain wordsSee what pharmacy access requires

Each numbered entry lets you look up the original finding

Your injury may still ache, giving you reason to check a promise. These BPC-157 TB-500 references let you find the supporting research. Entries [1]-[12] cover studies and reviews; [13]-[16] cover FDA pharmacy information. Links and study numbers help you reach the original accounts.

I'd check the substance tested before trusting a claim that your injury will heal. Most repair work described as “TB-500” work gave whole Thymosin Beta-4 [4][8]. None of the entries reports a fair comparison of BPC-157 + TB-500 together [9]. You can inspect the original studies below, but their number doesn't make up for that missing test.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. ↗
  6. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10:17078. ↗
  7. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. ↗
  8. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  9. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  10. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  11. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  12. Ruff D, et al. Safety and pharmacokinetics of intravenous thymosin beta 4 (Phase 1 single-dose escalation study); and 2021 first-in-human study of full-length thymosin beta-4. Reported human single-agent data for full-length Thymosin Beta-4, not the TB-500 heptapeptide. ↗
  13. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. On the page marked content current as of April 22, 2026, FDA lists BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' as withdrawn nominations that are no longer in Category 2, while retaining the published safety-risk descriptions. FDA, verified 2026-05-29. ↗
  14. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Definitions of Category 1 and Category 2, the 503A/503B framework, and the bulks-list nomination process. FDA, verified 2026-05-29. ↗
  15. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Public calendar listing BPC-157, KPV, TB-500, and MOTs-C as bulk drug substances 'being considered for inclusion on the 503A Bulks List' to be discussed at this scheduled meeting (a scheduled discussion, not a decision). FDA, verified 2026-05-29. ↗
  16. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (guidance landing page); and FDA compounding pages describing the licensed-prescriber-to-503A/503B access pathway and ingredient-eligibility rules. FDA, verified 2026-05-29. ↗
  17. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
  18. Ho ENM, et al.. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗
  19. Ruff D, et al.. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
  20. et al.. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗